Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex

被引:12
|
作者
Huang, Yu-Shan [1 ]
Wang, Jann-Tay [1 ,2 ]
Sheng, Wang-Huei [1 ]
Chuang, Yu-Chung [1 ,3 ]
Chang, Shan-Chwen [1 ,4 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[2] Natl Hlth Res Inst, Chunan, South Korea
[3] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
关键词
Carbapenem-resistant Acinetobacter baumannii; Fluoroquinolone; Sitafloxacin; DNA GYRASE; TOPOISOMERASE-IV; KLEBSIELLA-PNEUMONIAE; TIGECYCLINE; SUSCEPTIBILITY; EMERGENCE; COLISTIN; DU-6859A; FLUOROQUINOLONES; QUINOLONES;
D O I
10.1016/j.jmii.2014.02.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) complex has posed a great challenge to clinicians worldwide. Sitafloxacin has been shown to have in vitro activity against pathogens resistant to other fluoroquinolones. However, data comparing the anti-CRAB activity of sitafloxacin with that of other antimicrobial agents are limited. Methods: Genospecies were identified by 16S-23S ribosomal RNA intergenic spacer sequencing. Minimum inhibitory concentrations (MICs) were determined by an agar dilution method. Isolates with sitafloxacin MICs <= 2 mg/L were provisionally considered as susceptible to sitafloxacin. The MIC breakpoint for tigecycline susceptibility was 2 mg/L. Results: A total of 167 CRAB complex blood isolates (146 A. baumannii, 7 Acinetobacter pittii, and 14 Acinetobacter nosocomialis) were collected from January 2009 to December 2011. Around 90% of the A. baumannii isolates were resistant to amikacin, cefepime, ceftazidime, piperacillin/tazobactam, ampicillin/sulbactam, ciprofloxacin, and levofloxacin. By contrast, the rate of resistance to colistin, sitafloxacin, and tigecycline was relatively low (0%, 41.1%, and 65.1%, respectively). The MIC50 and MIC90 of ciprofloxacin, levofloxacin, and sitafloxacin were 128 mg/L and >128 mg/L; 16 mg/L and 64 mg/L; 2 mg/L and 8 mg/L, respectively. Compared with ciprofloxacin and levofloxacin, sitafloxacin had a significantly lower MIC (p < 0.001), and the rate of resistance to sitafloxacin was significantly lower than that to ciprofloxacin (97.9% vs. 41.1%, p < 0.001), levofloxacin (97.3% vs. 41.1%, p < 0.001), and tigecycline (p < 0.001). Conclusion: Sitafloxacin has acceptable in vitro activity against CRAB, even against isolates resistant to other fluoroquinolones. Sitafloxacin may be considered an alternative drug of choice in treating CRAB related infections. Copyright (C) 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
引用
收藏
页码:545 / 551
页数:7
相关论文
共 50 条
  • [1] In vitro activity of sitafloxacin against carbapenem-resistant Acinetobacter baumannii
    Thamlikitkul, Visanu
    Tiengrim, Surapee
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 284 - 285
  • [2] In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
    Nahid H Ahmed
    Kamaldeen Baba
    Cornelis Clay
    Ruth Lekalakala
    Anwar A Hoosen
    BMC Research Notes, 5 (1)
  • [3] In vitro activity of tigecycline against multiple resistant Acinetobacter baumannii and carbapenem resistant Klebsiella pneumoniae isolates
    Akan, Oezay Arikan
    Uysal, Sevil
    MIKROBIYOLOJI BULTENI, 2008, 42 (02): : 209 - 215
  • [4] In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
    Seifert, Harald
    Mueller, Carina
    Stefanik, Danuta
    Higgins, Paul G.
    Miller, Alita
    Kresken, Michael
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2616 - 2621
  • [5] In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
    Seifert, Harald
    Mueller, Carina
    Stefanik, Danuta
    Higgins, Paul G. G.
    Wohlfarth, Esther
    Kresken, Michael
    ANTIBIOTICS-BASEL, 2023, 12 (07):
  • [6] In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
    Livermore, David M.
    Mushtaq, Shazad
    Warner, Marina
    Woodford, Neil
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (06) : 3840 - 3844
  • [7] In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy
    Mezzatesta M.L.
    Trovato G.
    Gona F.
    Nicolosi V.M.
    Nicolosi D.
    Carattoli A.
    Fadda G.
    Nicoletti G.
    Stefani S.
    Annals of Clinical Microbiology and Antimicrobials, 7 (1)
  • [8] In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
    Quirino, Angela
    Cicino, Claudia
    Scaglione, Vincenzo
    Marascio, Nadia
    Serapide, Francesca
    Scarlata, Giuseppe Guido Maria
    Lionello, Rosaria
    Divenuto, Francesca
    La Gamba, Valentina
    Pavia, Grazia
    Russo, Alessandro
    Torti, Carlo
    Matera, Giovanni
    Trecarichi, Enrico Maria
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2023, 15 (01)
  • [9] Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii
    Xu, Nannan
    Wang, Gang
    Leng, Yan
    Dong, Xiaomeng
    Chen, Fengzhe
    Xing, Quantai
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (04) : 3485 - 3491
  • [10] Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii
    Douraghi, M.
    Ghalavand, Z.
    Rostami, M. Nateghi
    Zeraati, H.
    Aliramezani, A.
    Rahbar, M.
    Mohammadzadeh, M.
    Ghourchian, S.
    Boroumand, M. A.
    Abdollahi, A.
    JOURNAL OF APPLIED MICROBIOLOGY, 2016, 121 (02) : 401 - 407